搜尋
Galmed Pharmaceuticals Ltd
GLMD添加自選
0.570USD
-0.079-12.34%
收盤 07/02, 13:00（美東）報價延遲15分鐘
3.75M總市值
虧損本益比TTM
關於 Galmed Pharmaceuticals Ltd 公司
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Galmed Pharmaceuticals Ltd簡介
公司代碼GLMD
公司名稱Galmed Pharmaceuticals Ltd
上市日期Mar 13, 2014
CEOBaharaff (Allen)
員工數量3
證券類型Ordinary Share
年結日Mar 13
公司地址16 Tiomkin Street
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編6578317
電話97236938448
網址https://www.galmedpharma.com
公司代碼GLMD
上市日期Mar 13, 2014
CEOBaharaff (Allen)
Galmed Pharmaceuticals Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
13.96K
+77.62%
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
常見問題
Galmed Pharmaceuticals Ltd的前五大股東是誰？
Galmed Pharmaceuticals Ltd的前五大股東如下：Mr. Allen Baharaff
有多少機構持有Galmed Pharmaceuticals Ltd(GLMD)的股份？
截至2026Q1，共有30家機構持有Galmed Pharmaceuticals Ltd的股份，合計持有的股份價值約為224.38K，占公司總股份的3.40% 。與2025Q4相比，機構持股有所增加，增幅為75169.00。